Cardiome Pharma Corp. announced that its subsidiary, Correvio International Sàrl, has entered into an agreement with Eurolab Especialidades Medicinales de Eurofar S.R.L. to sell and distribute Brinavess (vernakalant intravenous) exclusively in Argentina. Under the terms of the agreement, Eurolab has agreed to specific annual commercial goals for Brinavess(TM). Financial details of the agreement have not been disclosed.
“This agreement with Eurolab allows for the continued availability of Brinavess to our customers in Argentina,” said Karim Lalji, Cardiome’s chief commercial officer. “As the third largest country in South America in terms of population, Argentina remains a key market for Brinavess as we continue to build the brand in this region.”
“We are excited to expand our hospital product offerings to our customers with the addition of Brinavess to our portfolio,” said Gabriel Menendez, general manager at Eurolab. “We are committed to making this important drug for the conversion of atrial fibrillation available to all of our customers throughout the country.”
Date: August 25, 2014
Source: Cardiome Pharma Corp.